Thermo Fisher Launches Royalty-Free Cell Line Kit

Thermo Fisher Scientific announced the launch of the Gibco™ CHOvantage™ GS Cell Line Development (CLD) Kit, featuring a game-changing royalty-free licensing model that eliminates ongoing technology fees throughout the commercial life of biologics products.

For biopharmaceutical developers, royalty obligations on cell line technology can significantly impact profitability over the product lifecycle. Thermo Fisher's new CHOvantage GS CLD Kit removes this financial burden by including research-use rights with purchase, avoiding these common fees during development. This offers developers complete ownership and control of their manufacturing process while maintaining the performance benefits of proven CHO cell line technology.

The platform combines a robust transposon-based vector system with Thermo Fisher's proven Efficient-Pro media and feeds, enabling researchers to generate high-performing, regulatory-ready CHO cell lines with protein titers of ≥7 g/L. By eliminating royalty fees, developers gain greater cost predictability and commercial flexibility.

This integrated approach accelerates cell line development while providing developers with unprecedented economic control. Customers can establish stable pools in as little as four weeks and support stable clone selection within 14 weeks - all without the long-term licensing burden.

This article has been republished from external sources. Note: Material may have been edited for clarity, length, or style. For more information, please contact the cited source.